Home / Pharmaceutical company intelligence
Arsons Pharmaceutical Industries (Pvt) Ltd site mark
Pharmaceutical company intelligence

Arsons Pharmaceutical Industries (Pvt) Ltd

Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.

Private pharmaceutical and surgical-products manufacturer · Lahore · Pakistan

Lahore-based pharmaceutical and surgical-products manufacturer established in 1986, producing oral solids, topicals, sachets and surgical dressings.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation25 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check9 Aug 2026Latest source-check date across this published portfolio
Latest effective price date1 Jul 2025Newest effective date among published current price records
Corporate profile evidence3 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Arsons Pharmaceutical Industries (Pvt.) Ltd.
Company type
Private pharmaceutical and surgical-products manufacturer
Address
2.5 KM Defence Road, Off Multan Road, Lahore, Punjab 53710, Pakistan · 53710
Phone
+92 310 0906222
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000514 Arsons Pharmaceutical Industries (Pvt) Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000514 41 linked products · source seen 25 Sep 2026 View source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx49public portfolio records represented
REG38unique registrations represented
IDX3indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR41current validated price records
G21generic molecules in indexed catalogue
DF3dosage-form groups
TA5therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage84%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage98%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixArsons Pharmaceutical Industries (Pvt) LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arsons-pharmaceutical-industries-pvt-ltdGenerated 25 Sep 2026Anti-infectives26 · 63%CNS & mental health6 · 15%Gastrointestinal & hepatology6 · 15%Pain & musculoskeletal2 · 5%Hematology & thrombosis1 · 2%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioArsons Pharmaceutical Industries (Pvt) LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arsons-pharmaceutical-industries-pvt-ltdGenerated 25 Sep 202641presentationsTablet27 · 66%Capsule8 · 20%Cream6 · 15%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionArsons Pharmaceutical Industries (Pvt) LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arsons-pharmaceutical-industries-pvt-ltdGenerated 25 Sep 202640comparable productsBelow peer median32 · 80%Near peer median4 · 10%Above peer median4 · 10%Company median price position-11.4%Lowest-price equivalents3Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsArsons Pharmaceutical Industries (Pvt) LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arsons-pharmaceutical-industries-pvt-ltdGenerated 25 Sep 2026Mediate Pharmaceutical Pvt Ltd18 shared86% overlapValor Pharmaceuticals18 shared86% overlapNeutro Pharma (Pvt.) Ltd.,18 shared86% overlapNabiqasim Industries (Pvt) Ltd.,17 shared81% overlapEpharm Laboratories16 shared76% overlapAmarant Pharmaceuticals Private Lim…16 shared76% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Formulation footprint

Dosage forms

Tablet27 products
Capsule8 products
Cream6 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median3280% of comparable products
Near market median4within ±5% of median
Above market median410% of comparable products
Lowest-price equivalents3ties included
Company median price position -11.4% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Regulatory & price activity

Observed database signals

Indexed registration numbers30Distinct registrations among indexed, published, presentation-validated products only
Verified price observations41
Products with a verified price41
Products with multiple price observations0
Source records with multiple versions41
Latest portfolio source check9 Aug 2026
Latest effective price date1 Jul 2025
Latest source observation25 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

38 unique registration(s) · 3 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Lopium Loperamide HCl 2 mg Capsule 10x10 074278 PKR 227.26 PKR 2.27/capsule 56% below median
Lopium Loperamide HCl 2 mg Capsule 10;s 074278 PKR 33.63 PKR 3.36/capsule 35% below median
Lopium Loperamide HCl 2 mg Capsule 6x10 074278 PKR 136.94 PKR 2.28/capsule 56% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Arsons Pharmaceutical Industries (Pvt) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 25, 2026, from https://medinfobase.com/company/arsons-pharmaceutical-industries-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.